Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10473
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDonnan, Geoffrey Aen
dc.date.accessioned2015-05-15T23:55:51Z
dc.date.available2015-05-15T23:55:51Z
dc.date.issued2007-11-29en
dc.identifier.citationStroke; A Journal of Cerebral Circulation 2007; 39(1): 242en
dc.identifier.govdoc18048866en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10473en
dc.description.abstractThere have now been numerous phase III trials of neuroprotection that have failed to live up to the expectations created by preclinical testing in animal models, the most recent of which was the second pivotal trial of the spin trap agent NXY-059. We have reached a stage at which research in this area should stop altogether or radical new approaches adopted. The purpose of this article is to review how we reached this stage and make recommendations for a new approach to neuroprotection research.The background to neuroprotection research is reviewed and its problems are highlighted based on the research of others and of our own research group. From this, a series of questions are posed that require answers if the field is to progress. A road map for future research is then proposed.The road map involves the following steps for putative neuroprotectants: (1) better proof of efficacy in animal models; (2) in vivo evidence of efficacy in human tissue using cell cultures or brain slices; (3) in vivo studies of their distribution in the normal and ischemic human brain, particularly focusing on the ischemic penumbra; (4) demonstration of efficacy in novel human models of cerebral ischemia; and (5) phase II and III clinical trails with penumbral selection using imaging techniques.The accumulated evidence suggests that neuroprotection failure in clinical trial is due to identifiable preclinical and clinical factors. Neuroprotection research should be pursued but with a very different and more rigorous approach.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherBenzenesulfonates.therapeutic useen
dc.subject.otherBrain Ischemia.drug therapy.prevention & controlen
dc.subject.otherCardiovascular Agents.therapeutic useen
dc.subject.otherClinical Trials, Phase II as Topicen
dc.subject.otherClinical Trials, Phase III as Topicen
dc.subject.otherDisease Models, Animalen
dc.subject.otherFree Radical Scavengers.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherNeuroprotective Agents.therapeutic useen
dc.subject.otherStroke.drug therapyen
dc.titleThe 2007 Feinberg lecture: a new road map for neuroprotection.en
dc.typeJournal Articleen
dc.identifier.journaltitleStrokeen
dc.identifier.affiliationNational Stroke Research Institute, Austin Health, University of Melbourne, Waterdale Road, Heidelberg Heights, 3081, Australiaen
dc.identifier.doi10.1161/STROKEAHA.107.493296en
dc.description.pages242en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/18048866en
dc.type.austinJournal Articleen
local.name.researcherDonnan, Geoffrey A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.